BCA
IOVA icon

Bray Capital Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Bray Capital Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$320K Buy
+43,290
New +$401K 0.09% 110

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Bray Capital Advisors's IOVA Position: Q4 2024 in Review

Bray Capital Advisors opened a new position in Iovance Biotherapeutics (IOVA) in Q4 2024: 43,290 shares worth $320K. The stake represents 0.09% of the portfolio and ranks #110 among its holdings.

301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • Bray Capital Advisors held 43,290 shares of Iovance Biotherapeutics worth $320K as of Q4 2024.
  • Iovance Biotherapeutics was a new Bray Capital Advisors position in Q4 2024.
  • Iovance Biotherapeutics made up 0.09% of Bray Capital Advisors's portfolio in Q4 2024, its #110 holding.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on Bray Capital Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.